Common nonmutational <i>NOTCH1</i> activation in chronic lymphocytic leukemia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28314854.
- Also identified by DOI 10.1073/pnas.1702564114 and PMC identifier 5389283.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Activating mutations of <i>NOTCH1</i> (a well-known oncogene in T-cell acute lymphoblastic leukemia) are present in ∼4-13% of chronic lymphocytic leukemia (CLL) cases, where they are associated with disease progression and chemorefractoriness. However, the specific role of <i>NOTCH1</i> in leukemogenesis remains to be established. Here, we report that the active intracellular portion of NOTCH1 (ICN1) is detectable in ∼50% of peripheral blood CLL cases lacking gene mutations. We identify a "NOTCH1 gene-expression signature" in CLL cells, and show that this signature is significantly enriched in primary CLL cases expressing ICN1, independent of <i>NOTCH1</i> mutation. NOTCH1 target genes include key regulators of B-cell proliferation, survival, and signal transduction. In particular, we show that NOTCH1 transactivates <i>MYC</i> via binding to B-cell-specific regulatory elements, thus implicating this oncogene in CLL development. These results significantly extend the role of <i>NOTCH1</i> in CLL pathogenesis, and have direct implications for specific therapeutic targeting.
Medical subject headings
- B-Lymphocytes
- Leukemia, Lymphocytic, Chronic, B-Cell
- Receptor, Notch1